HOME > TOP STORIES
TOP STORIES
-
BUSINESS 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
-
BUSINESS Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
-
BUSINESS New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
-
BUSINESS 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
-
BUSINESS Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
-
BUSINESS Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
-
BUSINESS MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
-
ACADEMIA Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
-
BUSINESS Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
-
ACADEMIA Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
-
REGULATORY Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
-
REGULATORY Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
-
BUSINESS MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
-
BUSINESS Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
-
BUSINESS Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
-
REGULATORY Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
-
REGULATORY MHLW Aims to Set Up Evaluation Index, Sakigake System for SaMD by March
June 18, 2021
-
BUSINESS Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
-
BUSINESS Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
-
BUSINESS Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
